{"success":true,"data":{"pressRelease":{"id":"160610","rtpr_id":"nGNX9g3cGC-20261005","ticker":"AVXL","exchange":"NASDAQ","all_tickers":["AVXL"],"title":"Portnoy Law Firm Announces Class Action on Behalf of Anavex Life Sciences Corp. Investors","author":"Globe Newswire","published_at":"2026-10-05T13:00:01.041Z","article_body":"LOS ANGELES, Oct. 05, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm\n(https://www.globenewswire.com/Tracker?data=DQqVt24ftPNxi47HO7oXyWAIxAPqJB9PG3hasblvipO1gClYRLVmYID12F0XnEYKpHuQC6ADq_sm6Ca37pDY1mhFZBrlhoMRiRmJ1bh-vtUkjMAbmDmU8cvKqUhGpKW1)\nadvises Anavex Life Sciences Corp., (“Anavex” or the \"Company\") (NASDAQ:\nAVXL) investors of a class action on behalf of investors that bought\nsecurities between November 26, 2025 and August 28, 2026, inclusive (the\n“Class Period”). Anavex investors have until November 30, 2026 to file a\nlead plaintiff motion.\n\nInvestors are encouraged to contact attorney Lesley F. Portnoy\n(https://www.globenewswire.com/Tracker?data=aQWVdV7On929dGxZRZzXIjvHiRUk7canE2QmXz2fpjz3QMM9aUvfu8KIiDq1eFauj1_kdDZDImnFVmdCoqohBrY5ZYZMC1_7LjVdMJ6sUxBz5lioZJp1F3RiPis_Dcbm), by\nphone 310-692-8883 or email\n(https://www.globenewswire.com/Tracker?data=cjfYDNqe8N8SBZ1HyD6ewAFwwfYEW8sqj0AckU7fUkyIzxfqhYHMOO3MWsEfdFjcJLs0tZqoiUaOILU20nD8JIKip1CruG1gEvkH7UBrp8w=):\nlesley@portnoylaw.com, to discuss their legal rights, or join the case via\nhttps://portnoylaw.com/anavex-life-sciences-corp. The Portnoy Law Firm can\nprovide a complimentary case evaluation and discuss investors’ options for\npursuing claims to recover their losses.\n\nThe Anavex class action complaint asserts that Defendants distributed false\nand misleading statements and omitted critical information throughout the\nClass Period, failing to reveal that: (i) Anavex suffered from deficient\ninternal control systems; (ii) the company minimized its exposure to potential\nregulatory hurdles stemming from improper actions by former Chief Executive\nOfficer Christopher Missling; and (iii) consequently, Defendants' public\nrepresentations regarding Anavex's business model, ongoing operations, and\nfuture growth lacked a sound foundation and were materially misleading during\nall relevant periods.\n\nOn May 6, 2026, Anavex submitted a Form 8-K Current Report to the U.S.\nSecurities and Exchange Commission (\"SEC\"), announcing that on April 30, 2026,\nan independent Special Committee of its Board of Directors ousted Chief\nExecutive Officer Christopher Missling, PhD \"for Cause,\" terminating his\nagreement immediately based on conduct conflicting with internal company\nstandards. Following this filing, Anavex shares dropped nearly 1%, as detailed\nin the action.\n\nSubsequent post-market disclosures on May 11, 2026, showed Anavex filing a\nForm 12b-25 Notice of Late Filing with the SEC, explaining its inability to\nsubmit its Quarterly Report on Form 10-Q for the quarter ending March 31,\n2026, on time due to an internal probe into issues surrounding Dr. Missling's\ntermination. Prompted by this notice, Anavex's share value fell almost 6%,\naccording to the lawsuit.\n\nLater, on August 28, 2026, during post-market hours, Anavex submitted an\namended Form 10-K/A Annual Report for the fiscal year ended September 30,\n2025. The amendment disclosed that the Special Committee's inquiry led\nmanagement and the Board's Audit Committee to determine that a material\nweakness in internal control over financial reporting existed as of September\n30, 2025, rendering its broader disclosure controls and procedures ineffective\nas of that date. Concurrently, the firm filed delayed quarterly reports for\nthe periods ending March 31, 2026, and June 30, 2026, confirming that\nmanagement found its internal financial reporting controls and disclosure\nprocedures ineffective across multiple quarters—specifically September 30,\n2025, December 31, 2025, March 31, 2026, and June 30, 2026—in the wake of\nthe former CEO's April 2026 dismissal. Upon these disclosures, Anavex stock\ndropped over 6%, as alleged in the complaint.\n\nThe Portnoy Law Firm represents investors in pursuing claims caused by\ncorporate wrongdoing. The Firm’s founding partner has recovered over $5.5\nbillion for aggrieved investors. Attorney advertising. Prior results do not\nguarantee similar outcomes.\n\nLesley F. Portnoy, Esq.\nAdmitted CA, NY and TX Bar\nlesley@portnoylaw.com\n310-692-8883\nwww.portnoylaw.com\n\nAttorney Advertising\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/ea0dd9c0-6e41-4d5a-ad27-b277677af6df)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX9g3cGC-20261005","title":"Portnoy Law Firm Announces Class Action on Behalf of Anavex Life Sciences Corp. Investors","author":"Globe Newswire","ticker":"AVXL","created":"2026-10-05T13:00:01.041Z","tickers":["AVXL"],"exchange":"NASDAQ","article_body":"LOS ANGELES, Oct. 05, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm\n(https://www.globenewswire.com/Tracker?data=DQqVt24ftPNxi47HO7oXyWAIxAPqJB9PG3hasblvipO1gClYRLVmYID12F0XnEYKpHuQC6ADq_sm6Ca37pDY1mhFZBrlhoMRiRmJ1bh-vtUkjMAbmDmU8cvKqUhGpKW1)\nadvises Anavex Life Sciences Corp., (“Anavex” or the \"Company\") (NASDAQ:\nAVXL) investors of a class action on behalf of investors that bought\nsecurities between November 26, 2025 and August 28, 2026, inclusive (the\n“Class Period”). Anavex investors have until November 30, 2026 to file a\nlead plaintiff motion.\n\nInvestors are encouraged to contact attorney Lesley F. Portnoy\n(https://www.globenewswire.com/Tracker?data=aQWVdV7On929dGxZRZzXIjvHiRUk7canE2QmXz2fpjz3QMM9aUvfu8KIiDq1eFauj1_kdDZDImnFVmdCoqohBrY5ZYZMC1_7LjVdMJ6sUxBz5lioZJp1F3RiPis_Dcbm), by\nphone 310-692-8883 or email\n(https://www.globenewswire.com/Tracker?data=cjfYDNqe8N8SBZ1HyD6ewAFwwfYEW8sqj0AckU7fUkyIzxfqhYHMOO3MWsEfdFjcJLs0tZqoiUaOILU20nD8JIKip1CruG1gEvkH7UBrp8w=):\nlesley@portnoylaw.com, to discuss their legal rights, or join the case via\nhttps://portnoylaw.com/anavex-life-sciences-corp. The Portnoy Law Firm can\nprovide a complimentary case evaluation and discuss investors’ options for\npursuing claims to recover their losses.\n\nThe Anavex class action complaint asserts that Defendants distributed false\nand misleading statements and omitted critical information throughout the\nClass Period, failing to reveal that: (i) Anavex suffered from deficient\ninternal control systems; (ii) the company minimized its exposure to potential\nregulatory hurdles stemming from improper actions by former Chief Executive\nOfficer Christopher Missling; and (iii) consequently, Defendants' public\nrepresentations regarding Anavex's business model, ongoing operations, and\nfuture growth lacked a sound foundation and were materially misleading during\nall relevant periods.\n\nOn May 6, 2026, Anavex submitted a Form 8-K Current Report to the U.S.\nSecurities and Exchange Commission (\"SEC\"), announcing that on April 30, 2026,\nan independent Special Committee of its Board of Directors ousted Chief\nExecutive Officer Christopher Missling, PhD \"for Cause,\" terminating his\nagreement immediately based on conduct conflicting with internal company\nstandards. Following this filing, Anavex shares dropped nearly 1%, as detailed\nin the action.\n\nSubsequent post-market disclosures on May 11, 2026, showed Anavex filing a\nForm 12b-25 Notice of Late Filing with the SEC, explaining its inability to\nsubmit its Quarterly Report on Form 10-Q for the quarter ending March 31,\n2026, on time due to an internal probe into issues surrounding Dr. Missling's\ntermination. Prompted by this notice, Anavex's share value fell almost 6%,\naccording to the lawsuit.\n\nLater, on August 28, 2026, during post-market hours, Anavex submitted an\namended Form 10-K/A Annual Report for the fiscal year ended September 30,\n2025. The amendment disclosed that the Special Committee's inquiry led\nmanagement and the Board's Audit Committee to determine that a material\nweakness in internal control over financial reporting existed as of September\n30, 2025, rendering its broader disclosure controls and procedures ineffective\nas of that date. Concurrently, the firm filed delayed quarterly reports for\nthe periods ending March 31, 2026, and June 30, 2026, confirming that\nmanagement found its internal financial reporting controls and disclosure\nprocedures ineffective across multiple quarters—specifically September 30,\n2025, December 31, 2025, March 31, 2026, and June 30, 2026—in the wake of\nthe former CEO's April 2026 dismissal. Upon these disclosures, Anavex stock\ndropped over 6%, as alleged in the complaint.\n\nThe Portnoy Law Firm represents investors in pursuing claims caused by\ncorporate wrongdoing. The Firm’s founding partner has recovered over $5.5\nbillion for aggrieved investors. Attorney advertising. Prior results do not\nguarantee similar outcomes.\n\nLesley F. Portnoy, Esq.\nAdmitted CA, NY and TX Bar\nlesley@portnoylaw.com\n310-692-8883\nwww.portnoylaw.com\n\nAttorney Advertising\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/ea0dd9c0-6e41-4d5a-ad27-b277677af6df)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-05T13:00:02.231457472Z","server_sent_at_ms":1791205202231},"received_at":"2026-10-05T13:00:02.283Z","source_url":null},"analysis":{"id":"149166","press_release_id":"160610","analysis_json":{"redFlags":["underlying material weakness in internal control over financial reporting across multiple quarters","former CEO terminated for cause following special committee investigation"],"eventType":"legal_litigation","narrative":"The Portnoy Law Firm announced a class action on behalf of Anavex Life Sciences investors who bought shares between November 26, 2025 and August 28, 2026, with a lead plaintiff deadline of November 30, 2026.\n\nThe complaint alleges misleading statements, deficient internal controls, and minimized regulatory exposure tied to former CEO Christopher Missling, who was ousted for cause in April 2026.\n\nThis is a law-firm solicitation, not new issuer disclosure; the underlying 12b-25 late filing and material-weakness disclosures were previously made by the company.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation -- suppress."},"keyFigures":{},"namedEntities":{"people":[{"name":"Lesley F. Portnoy","role":"attorney, Portnoy Law Firm"},{"name":"Christopher Missling","role":"former CEO of Anavex (terminated for cause)"}],"products":[],"companies":[{"name":"Anavex Life Sciences Corp.","ticker":"AVXL","relationship":"subject of class action"},{"name":"Portnoy Law Firm","relationship":"plaintiff law firm"}],"dollarAmounts":[{"amount":"$5.5 billion","context":"prior recovery claims by Portnoy Law Firm founding partner"}]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm solicitation issued by the Portnoy Law Firm seeking lead plaintiffs. No new issuer disclosure; the underlying governance issues were previously disclosed by the company."},"tickerRelevance":{"others":[],"primary":"AVXL"},"globalImportance":15,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap biotech","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"The Portnoy Law Firm announced a class action on behalf of Anavex Life Sciences investors who bought shares between November 26, 2025 and August 28, 2026, with a lead plaintiff deadline of November 30, 2026.\n\nThe complaint alleges misleading statements, deficient internal controls, and minimized regulatory exposure tied to former CEO Christopher Missling, who was ousted for cause in April 2026.\n\nThis is a law-firm solicitation, not new issuer disclosure; the underlying 12b-25 late filing and material-weakness disclosures were previously made by the company.","key_figures":{},"named_entities":{"people":[{"name":"Lesley F. Portnoy","role":"attorney, Portnoy Law Firm"},{"name":"Christopher Missling","role":"former CEO of Anavex (terminated for cause)"}],"products":[],"companies":[{"name":"Anavex Life Sciences Corp.","ticker":"AVXL","relationship":"subject of class action"},{"name":"Portnoy Law Firm","relationship":"plaintiff law firm"}],"dollarAmounts":[{"amount":"$5.5 billion","context":"prior recovery claims by Portnoy Law Firm founding partner"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-05T13:00:10.686Z","global_importance":15,"audience_relevance":10,"importance_components":{"tickerTier":"small-cap biotech","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"durationMs":4739,"modelName":"glm-5.3-flashx"}}